Mubritinib
Alternative Names: TAK-165Latest Information Update: 02 Oct 2021
At a glance
- Originator Takeda
- Class Antineoplastics; Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 06 Oct 2004 Discontinued - Phase-I for Solid tumours in USA (PO)
- 06 Oct 2004 Discontinued - Preclinical for Solid tumours in Japan (PO)
- 25 Jul 2003 Phase-I clinical trials for Solid tumours in USA (PO)